Many persistent organic pollutants (POPs) can be measured in human breast milk samples collected worldwide. Early exposure to POPs through breastfeeding significantly increases children's body burden ([@r25]; [@r31]; [@r35]) and is thought to be the primary determinant of children's blood levels until at least 7 years of age ([@r4]). The impact of postnatal intake of POPs on child development has been assessed in epidemiologic studies but results are mostly inconsistent ([@r20]), possibly because of limitations in current methods used to assess exposure.

A handful of approaches were proposed to characterize children's exposure to POPs via breastfeeding in epidemiologic studies. [@r15] used the concentration of polychlorinated biphenyls (PCBs) and dioxins in breast milk lipids as an estimate of postnatal exposure. To account for duration of lactation, several epidemiologic studies multiplied breast milk concentration by the duration of breastfeeding ([@r11]; [@r18]; [@r22]; [@r38]). [@r30] developed a similar exposure metric, but they distinguished exclusive from partial breastfeeding periods, and assumed that breast milk consumption when children were also given other supplements is half that of children being exclusively breastfed. Direct measurement of POPs in children's blood lipids was also used as a proxy of postnatal internal exposure ([@r6]; [@r11]; [@r18]; [@r33]; [@r40]). None of these methods generates complete profiles of tissue or blood levels across development. Overall estimates may fail to detect associations with POPs that affect health during narrow time windows of exposure only ([@r13]).

In a previous longitudinal birth cohort study, we estimated children's blood POP profile over the first year of life with a validated physiologically based pharmacokinetic (PBPK) model ([@r45]). Generating profiles of postnatal blood PCB-153 levels allowed us to assess exposure during different windows, an approach that led us to identify a postnatal interval of susceptibility to neurotoxic insults. The PBPK model was, however, quite complex and did not allow the incorporation of certain individual variables such as gestational age, weight gain during pregnancy, and weight loss after delivery, all of which may modulate children's exposure. Furthermore, this model required information on mothers' and children's height at different times, which may not be systematically documented in epidemiologic studies. Finally, the model was validated only for simulations based on maternal blood levels and only until 6 months of age.

To overcome these limitations and ease the use of toxicokinetic modeling in epidemiologic studies, we developed a simplified model to simulate blood POP levels across childhood and validated it to 45 months of age using blood levels of children enrolled in two longitudinal birth cohorts. We also assessed model validity for simulations based on levels in different samples: maternal blood, cord blood, and breast milk. We confined our analyses to four PCB congeners \[International Union of Pure and Applied Chemistry (IUPAC) no. 118, 153, 170, and 180\], 1,1-dichloro-2,2-bis(*p*-chlorophenyl)ethylene (*p,p´*-DDE), 1,1,1-trichloro-2,2-bis(*p*-chlorophenyl)ethane (*p,p´*-DDT) and hexachlorobenzene (HCB).

Methods
=======

*Conceptual representation.* We developed this model based on the assumption that POPs distribute almost exclusively in lipids ([@r9]; [@r12]). Therefore, we represented both the mother and child as lipid compartments (including blood lipids) connected through placental diffusion and excretion/intake of breast milk ([Figure 1](#f1){ref-type="fig"}). The mother was exposed to POPs through ingestion of contaminated food. The child was exposed prenatally through placental diffusion and postnatally through consumption of breast milk.

![Conceptual representation of the toxicokinetic model.](ehp.1205552.g001){#f1}

*Parameterization.* The complete set of parameters and equations is available in the model code provided in Supplemental Material (<http://dx.doi.org/10.1289/ehp.1205552>). Briefly, the kinetics of POPs are described as follows:

Absorption. POPs in the gastrointestinal tract of both mothers and children were assumed to be fully absorbed as suggested by results from experimental studies ([@r27]).

Distribution. Following absorption, POPs were assumed to distribute homogeneously in body lipids. During pregnancy, POPs were allowed to partition equally in maternal and fetal lipids. Mothers' and children's lipid volumes were scaled to individual-specific age and body weight according to data from [@r10] and the International Commission on Radiological Protection (ICRP 2002). The percentage of lipids in fetal tissues across pregnancy was set to values at birth---15% for males and 14% for females. Gain in body fat mass during pregnancy was calculated as the difference between weight gain and increase in lean tissues (fetus, uterus, placenta, amniotic fluid, blood, breasts, and extracellular and extravascular fluid). Fetal growth was based on a general growth curve (ICRP 2002) and individual birth weight, whereas increase in other lean tissues was the same for all women (increase of 5.8 kg at the end of pregnancy) (ICRP 2002). After delivery, the difference between weight and prepregnancy weight was considered to be strictly attributable to adipose tissue. This assumption was based on a study reporting that lean tissue gain during pregnancy is rapidly lost after delivery ([@r7]). The additional adipose tissue during and after pregnancy was assumed to be composed of 75% lipids ([@r3]).

Metabolism and excretion. Elimination due to biotransformation and fecal excretion was set as an output from mother and children compartments with rates based on half-lives derived from cross-sectional data \[PCB-118: 9.3 years; PCB-138: 10.8 years; PCB-153: 14.4 years; PCB-170: 15.5 years; PCB-180: 11.5 years ([@r37]); *p,p´-*DDT: \~ 5 years ([@r42])\] and longitudinal data \[*p,p´*-DDE: 13 years ([@r46]); HCB: 6 years ([@r44])\]. Elimination rates (*K*~el~) were calculated as follows:

*K*~el~ = ln(2)/half-life. \[1\]

Excretion of POPs in breast milk lipids was driven by children's breast milk consumption and breast milk lipid content. Milk consumption during exclusive breastfeeding was described based on data from [@r41], expressed on the basis of children's body weight and age by [@r1]:

Hourly milk intake (L/kg body weight)  = --0.0024 × Age (years) + 0.0063. \[2\]

From 12 until 24 months of age, we described breast milk consumption based on partial breastfeeding data published by [@r21]:

Hourly milk intake (L)  = --0.0086 × Age (years) + 0.0188. \[3\]

We described breast milk lipids based on concentrations published by [@r5] and [@r1]:

Fraction of lipids in breast milk (kg/L) = 0.0034 × ln(Age \[years\]) + 0.0414. \[4\]

*Model inputs.* To generate postnatal exposure profiles, the model requires the inclusion of certain variables that are relevant to POP toxicokinetics: age of mother at delivery, prepregnancy body weight, child's birth weight, child's weight at one or more postnatal times (along with the time of measurement), duration of exclusive breastfeeding, duration of partial breastfeeding (when the child is fed both breast milk and other food), child's sex, levels of POPs in maternal blood, cord blood or breast milk lipids (with the time of sampling), and half-life of the POP to be modeled. In addition to these essential variables, the model can incorporate data on: weight gain during pregnancy and weight changes after delivery, gestational age at birth, and percentage of food intake attributable to breast milk during partial breastfeeding.

*Inuit birth cohort.* Pregnant Inuit women from Northern Quebec (Canada) were invited to participate in this longitudinal birth cohort shortly after their first prenatal visit ([@r29]). Maternal and cord blood samples were collected at the time of delivery. Approximately 1 month after delivery, a sample of breast milk was obtained from mothers. Children's blood was drawn around 6 months (range, 1--14 months) after birth. A large array of organochlorines including pesticides and PCBs was analyzed in these samples, as described by [@r29]. In this cohort, information on breastfeeding was collected 6 and 11 months after delivery. Only mother--child dyads with POP levels above the limit of detection and available data on duration of exclusive and partial breastfeeding were included in the validation analyses. Missing maternal and child values for other variables were replaced by the variable's mean value. A total of 160 children were included in the analyses. Detailed informed consent was provided by each participating mother. The research procedures were approved by the human subjects committees of Laval University and Wayne State University.

*Slovak birth cohort.* Women from the regions of Michalovce and Svidnik/Stropkov in Slovakia were invited to enroll in this longitudinal birth cohort at the time of delivery ([@r14]). Maternal and cord blood samples were collected at the time of delivery. Blood samples were drawn from children at 6 months (range, 5.5--11.7), 16 months (range, 11.8--22.0), and 45 months of age (range, 33.0--69.1). Mothers enrolled in this study were asked about their breastfeeding practices 6 months and 16 months after delivery. Available data on the duration of exclusive and partial breastfeeding and PCB levels above the limit of detection were the only inclusion criteria for validation analyses. A total of 795 children were included in these analyses. This study was approved by Institutional Review Boards of the University of California, Davis (USA) and the Slovak Medical University in Bratislava, Slovakia. Written informed consent was provided by all participants, and consent was given by the parents for infants to participate in the study.

*Validation.* We validated the model following the steps presented in [Figure 2](#f2){ref-type="fig"}. For both cohorts, individual-specific variables on age at delivery, prepregnancy weight, child weight, duration of exclusive and partial breastfeeding, and child sex were incorporated in the toxicokinetic model. Average values were used for weight gain during pregnancy (14.5 kg; [@r7]) and weight changes postpartum (2 kg above prepregnancy weight 0.5 year after delivery; [@r7]) because individual data were not collected in these cohorts. In addition, we assumed that maternal weight returned to prepregnancy weight by the end of the first year, and that breast milk consumption during periods of partial breastfeeding was 50% of the amount consumed by exclusively breastfed children at the same age.

![Steps undertaken to validate the toxicokinetic model.](ehp.1205552.g002){#f2}

We first estimated maternal lifetime daily POP oral intake based on levels measured in maternal blood at delivery, cord blood, or breast milk. We subsequently performed simulations of children's POP levels for each of the available samples (maternal blood, cord blood, and/or breast milk) and compared simulated with measured POP levels by linear regression to determine how much of the variability in measured blood levels could be explained by the toxicokinetic model based on the coefficient of determination (*R*^2^). To avoid bias related to heteroskedasticity, measured and simulated levels were log-transformed before regression analyses.

*Global sensitivity analysis.* To quantify the impact of the various model inputs on simulated children's blood POP levels, we ran a sensitivity analysis where model input values were iteratively sampled from specified ranges: prepregnancy body weight (51--114 kg; [@r26]), weight gain during pregnancy (7.6--32.0 kg; [@r43]), postpartum weight changes (--12 to 26 kg 1 year after delivery; [@r39]), gestational age (22--42 weeks; [@r23]), birth weight (0.34--4.9 kg; [@r23]), weight at 6 months (6.4--9.8 kg; [@r24]), weight at 1 year (8.4--12.8 kg; [@r24]), weight at 3 years (11.8--18 kg; [@r24]), duration of exclusive breastfeeding (0--12 months; arbitrary), duration of partial breastfeeding (0--45 months; arbitrary), fraction of food intake attributable to breast milk during partial breastfeeding (0.1--0.9; arbitrary, single percentage used for the whole period of partial breastfeeding).

In the model, certain parameters are likely to interact with each other (e.g., duration of partial breastfeeding and fraction of food intake attributable to breast milk), and the sensitivities reported should ideally account for these interactions as thoroughly as possible. Commonly employed one-at-a-time local sensitivity analyses (where only one parameter is varied while the others are kept constant) cannot account for these interactive effects. For this reason, we opted for an extended Fourier amplitude sensitivity analysis (eFAST) ([@r28]). Although more computationally intensive, this global approach allows the quantitative calculation of the relative contributions for a set of parameters over ranges of physiologically appropriate values---a clear advantage over local sensitivity analyses. Global sensitivity (total effects) obtained for each parameter at different time points (6, 16, and 45 months) was used to indicate its relative influence on the model output. We ran separate sensitivity analyses for PCB-153, a compound with a relatively long half-life, and *p,p´-*DDT, a compound with a relatively short half-life, in boys and in girls.

*Exposure misclassification in epidemiologic studies.* To illustrate that a commonly employed method to estimate postnatal exposure can lead to exposure misclassification, we simulated profiles of blood PCB-153 levels in two Inuit children who had the same overall lactational exposure when estimated based only on the duration of breastfeeding and the concentration in breast milk (weeks breastfeeding × ng/g milk lipids = \~ 4,700).

*Model and software.* Toxicokinetic modeling was performed using acslX (Aegis Technologies Group, Inc., Huntsville, AL, USA) and Microsoft Excel® 2007 (Microsoft, Redmond, WA, USA). Statistical analyses were conducted using SPSS for Windows statistical package version 20 (IBM, Chicago, IL, USA). The model code and automation script are provided in the Supplemental Material (<http://dx.doi.org/10.1289/ehp.1205552>).

Results
=======

Inuit mothers who ever breastfed their child (89%) tended to do so exclusively for a longer period than their Slovak counterparts (100%). Moreover, the duration of exclusive breastfeeding was more variable in the Inuit cohort ([Table 1](#t1){ref-type="table"}). Levels of PCBs and other organochlorines in maternal and cord blood lipids were higher in the Slovak cohort, except for PCB-118, but the variability in levels, as indicated by 5th--95th percentile ranges and their ratios, was relatively comparable ([Table 2](#t2){ref-type="table"}).

###### 

Demographic characteristics \[mean (5th--95th percentile)\].

  Characteristic                     Inuits (n = 160)    Slovaks (n = 795)
  ---------------------------------- ------------------- -------------------
  Age at delivery (years)            25 (17--36)         26 (19--34)
  Prepregnancy weight (kg)           71.2 (55.3--93.7)   60.2 (46.0--81.0)
  Gestational age at birth (weeks)   39 (36--41)         40 (38--41)
  Birth weight (kg)                  3.5 (2.4--4.4)      3.4 (2.6--4.2)
  Child weight at 6 months (kg)      9.6 (7.8--11.5)     7.9 (6.2--9.6)
  Child weight at 16 months (kg)     ---                 11.7 (9.0--14.3)
  Child weight at 45 months (kg)     ---                 17.0 (13.0--22.6)
  Exclusive breastfeeding (days)     185 (6--370)        96 (30--183)
  Total breastfeeding (days)         220 (7--391)        205 (30--487)

###### 

Median POP levels (ng/g lipids) in maternal blood at delivery, cord blood, and breast milk samples collected in the Inuit and Slovak studies.

  Compound                                                        Maternal blood     Cord blood         Breast milk                         
  --------------------------------------------------------------- ------------------ ------------------ ----------------- ----------------- ------------------
  PCB-118                                                         14 (5--46)         8 (1--45)          12 (4--57)        4 (1--38)         18 (6--71)
  PCB-138                                                         59 (21--167)       90 (32--360)       51 (16--200)      77 (21--345)      70 (22--262)
  PCB-153                                                         104 (32--336)      140 (53--553)      78 (22--319)      111 (34--457)     118 (41--412)
  PCB-170                                                         17 (6--65)         54 (20--209)       12 (4--51)        36 (8--154)       17 (4--75)
  PCB-180                                                         44 (14--155)       127 (49--523)      28 (9--122)       89 (25--376)      44 (15--167)
  p,p´-DDE                                                        281 (107--1,023)   432 (108--1,430)   276 (98--1,060)   409 (91--1,480)   384 (132--1,501)
  p,p´-DDT                                                        14 (3--38)         21 (7--82)         14 (5--40)        17 (4--65)        30 (8--95)
  HCB                                                             40 (15--122)       65 (5--302)        40 (17--148)      73 (5--329)       48 (15--133)
  Values in parentheses represent the 5th and 95th percentiles.                                                                             

*Accuracy of simulations for different compounds.* There was little variation in model accuracy across PCB congeners in both cohorts for a given sample type and age, although *R*^2^ of measured against simulated levels were consistently higher in the Inuit cohort than in the Slovak cohort ([Table 3](#t3){ref-type="table"}). In the Slovak cohort, the explained variability was somewhat lower for *p,p´-*DDE and HCB than for PCBs. Model accuracy was lower for *p,p´-*DDT than for other compounds in the Inuit cohort.

###### 

Regression analyses of blood POP levels measured at 6, 16, or 45 months of age against levels simulated from measured values in cord blood, maternal blood (at delivery), or breast milk (collected approximately 1 month postpartum).

  Compound                                                                                                   Inuit cohort (months)   Slovak cohort (months)                                             
  ---------------------------------------------------------------------------------------------------------- ----------------------- ------------------------ ------ ------ ------ ------ ------ ------ ------
  PCB-118                                                                                                                                                                                               
  R2                                                                                                         0.74                    0.73                     0.63   0.52   0.46   0.33   0.55   0.41   0.33
  n                                                                                                          60                      126                      112    205    726    404    215    728    390
  PCB-138                                                                                                                                                                                               
  R2                                                                                                         0.75                    0.80                     0.63   0.59   0.49   0.49   0.60   0.54   0.51
  n                                                                                                          79                      147                      118    205    726    405    216    728    391
  PCB-153                                                                                                                                                                                               
  R2                                                                                                         0.74                    0.81                     0.65   0.57   0.51   0.50   0.59   0.53   0.51
  N                                                                                                          79                      150                      118    205    726    405    216    728    391
  PCB-170                                                                                                                                                                                               
  R2                                                                                                         0.72                    0.65                     0.66   0.50   0.46   0.45   0.56   0.53   0.50
  n                                                                                                          51                      111                      103    205    726    405    216    728    391
  PCB-180                                                                                                                                                                                               
  R2                                                                                                         0.75                    0.77                     0.63   0.59   0.51   0.50   0.60   0.54   0.51
  n                                                                                                          78                      143                      117    205    726    405    216    728    391
  p,p´-DDE                                                                                                                                                                                              
  R2                                                                                                         0.76                    0.83                     0.62   0.40   0.48   0.39   0.49   0.44   0.39
  n                                                                                                          81                      156                      118    205    726    405    216    728    391
  p,p´-DDT                                                                                                                                                                                              
  R2                                                                                                         0.52                    0.47                     0.49   0.57   0.44   0.31   0.58   0.45   0.30
  n                                                                                                          48                      103                      102    205    726    406    216    717    391
  HCB                                                                                                                                                                                                   
  R2                                                                                                         0.63                    0.74                     0.59   0.44   0.40   0.13   0.40   0.37   0.10
  n                                                                                                          66                      144                      116    198    718    395    210    723    383
  R2 values represent the fraction of variability in measured levels explained by the toxicokinetic model.                                                                                              

*Sample used to simulate children's blood levels.* In the Slovak cohort, the model had similar predictiveness at each age regardless of the type of sample (cord blood or maternal blood at delivery) used to simulate children's blood levels ([Table 3](#t3){ref-type="table"}). Predictiveness was also similar between cord blood and maternal blood for the Inuit cohort, but accuracy was lower for simulations based on milk samples ([Table 3](#t3){ref-type="table"}) and tended to overestimate children's blood levels by an average of 60% ([Figure 3](#f3){ref-type="fig"}).

![PCB-153 levels measured in children's blood in the Inuit cohort plotted against blood PCB-153 levels simulated from cord blood, maternal blood at delivery, or breast milk concentrations. Axes are on a logarithmic scale.](ehp.1205552.g003){#f3}

*Validity across development.* Although the predictiveness of simulations for the Slovak cohort decreased as the age of children at blood sample measurement increased, the loss in accuracy was small for most compounds ([Table 3](#t3){ref-type="table"}, [Figure 4](#f4){ref-type="fig"}). However, the decrease in *R*^2^ values was more pronounced for PCB-118, *p,p´-*DDT, and HCB, the compounds with the shortest half-lives.

![PCB-153 levels measured in children's blood at 6, 16, and 45 months of age in the Slovak cohort plotted against blood PCB-153 levels simulated from cord blood concentrations. Axes are on a logarithmic scale.](ehp.1205552.g004){#f4}

*Global sensitivity analysis.* The influence of model inputs on children's blood POP levels was assessed using eFAST global sensitivity analysis. The global sensitivity (total effects) of the different parameters on POP levels varied depending on children's age ([Figure 5](#f5){ref-type="fig"}). Overall, breastfeeding-related parameters had a greater relative influence on simulated POP levels from 6 months up to 45 months. For example, nearly half the variability in simulated blood POP levels at 6 months of age could be attributed to the influence of duration of breastfeeding, through first- or higher-order effects. As expected, weight gain during pregnancy had a greater influence on simulated levels at 6 months than at 16 or 45 months, whereas postpartum weight changes became more influential over time. The relative sensitivity of estimates to changes in the child's weight was lower than the sensitivity to changes in breastfeeding and maternal weight parameters, except for birth weight, which had a relatively strong influence on simulated levels at 6 months. Prepregnancy body weight and gestational age at birth had little influence on estimates.

![Global sensitivity analysis (eFAST) of the influence of model inputs on estimates of blood PCB-153 levels in girls at 6, 16, and 45 months of age. Results of global sensitivity analyses were comparable for *p,p´*-DDT and according to sex.](ehp.1205552.g005){#f5}

*Exposure misclassification.* There was a striking difference between the simulated profiles of PCB-153 levels of two Inuit children with the same overall lactational exposure calculated with the commonly employed approach of multiplying milk levels by the duration of breastfeeding ([Figure 6](#f6){ref-type="fig"}). This was especially true at 3 months of age, when blood PCB-153 level in the child exposed to the highest breast milk level (639 ng/g lipids) was more than three times that of the other child (193 ng/g lipids).

![Blood PCB-153 profiles of two Inuit children for whom the commonly employed approach to estimate overall exposures suggests comparable exposure (specifically, weeks of exclusive breastfeeding × ng/g milk lipids = \~ 4,700).](ehp.1205552.g006){#f6}

Discussion
==========

Adequate estimation of exposure to POPs through breastfeeding is critical for characterizing associations between postnatal exposure and children's health in epidemiologic studies. Here, we developed a simple toxicokinetic model that can simulate complete children's blood POP profiles based on cord blood, maternal blood, or breast milk levels and assessed its accuracy by comparing simulated blood levels to levels measured in children from two longitudinal birth cohorts. Using this model, we have shown that estimations based solely on breast milk levels and duration of breastfeeding may lead to exposure misclassification ([Figure 6](#f6){ref-type="fig"}).

Model predictiveness ranged from weak (*R*^2^ = 0.10) to high (*R*^2^ = 0.83) depending on the cohort, the compound, the sample used to simulate children's blood levels, and the age of the child when blood was collected for measurement. *R*^2^ values at 6 months of age were higher in the Inuit cohort than in the Slovak cohort, but *R*^2^ values cannot be compared across these studies because they may be influenced by sample size. Predictiveness also varied depending on the modeled chemical, although the compounds for which the model showed poorer accuracy differed between the Inuit (*p,p´-*DDT) and Slovak (*p,p´-*DDE and HCB) studies. Possible causes for divergence in model accuracy include population-specific physiologic characteristics, variability in the percentage of food intake attributable to breast milk during partial breastfeeding, and differences in analytic precision between laboratories.

*R*^2^ values also varied depending on the sample used to simulate children's exposure. Simulations based on maternal blood concentrations at delivery generally gave the best predictions, closely followed by those based on cord blood. When simulations were based on breast milk concentrations collected approximately 1 month postpartum, *R*^2^ values were slightly lower and children's blood levels were overestimated, likely because of methods used to adjust for lipids. Whereas lipids in breast milk are almost exclusively neutral triacyglycerol ([@r19]) in which POPs partition, blood contains phospholipids that bind lipophilic compounds with lower affinity ([@r34]). The usual method to adjust for blood lipids ([@r32]) includes phospholipids and leads to a 40% overestimation of blood neutral lipids when compared with breast milk. This compares well with our 60% overestimation of children's blood levels.

The model's ability to estimate blood levels of children in the Slovak cohort decreased only slightly between 6 months and 45 months of age for most compounds, potentially because breastfeeding remains the main determinant of children's blood levels throughout this period. In the same cohort of Inuits, [@r2] could explain close to 50% of the variability in PCB-153 blood concentration in a group of 87 children at 6 months based solely on the duration of exclusive breastfeeding. When both maternal blood concentration and duration of breastfeeding were included in the regression model, this percentage increased to 66%. Similarly, [@r17] could explain 60% of the variance in blood levels of 107 children at 4 years of age based on maternal milk PCB and weeks of breastfeeding, whereas children's fish consumption had little relation to measured blood PCB levels. In 7-year-old Faroese children, the duration of breastfeeding was the primary predictor of blood POP levels, followed by body mass index and intake through diet ([@r4]). These studies concur with our results suggesting that, even at high dietary exposures, breastfeeding is a primary predictor of children's blood POP levels up to 45 months of age.

Because epidemiologic questionnaires are invariably burdened with missing values and desired information is not systematically collected (e.g., weight loss postpartum), use of this toxicokinetic tool requires dealing with missing model inputs. In global sensitivity analyses, we showed that breastfeeding parameters are highly influential, so availability of information on breastfeeding is paramount to achieve precise estimations with the PBPK model. The absence of nursing information should therefore be considered an exclusion criterion in studies on postnatal exposure to POPs. Weight gain during pregnancy and weight changes after delivery also proved to be influential. Variations in body weight, which indicate fluctuations in maternal body lipids, have been shown to modulate POP levels in blood lipids and subcutaneous adipose tissue ([@r8]), thereby affecting breast milk levels and, in turn, children's exposure. Using average weight variation during and after pregnancy, as we did in this validation study, likely reduces model accuracy. On the other hand, child weight, gestational age at birth, and prepregnancy maternal weight displayed a relatively small influence on children's blood levels. Therefore, imputation of missing values can be performed without compromising model precision.

The model presented herein generates individualized exposure profiles from birth to 45 months of age from which blood POP levels can be determined for any period of interest \[[Figure 6](#f6){ref-type="fig"}; see also Supplemental Material, Figure S1 (<http://dx.doi.org/10.1289/ehp.1205552>)\]. This is particularly useful when estimating the effects of POPs on systems that undergo specific developmental processes during constrained postnatal time frames, such as during brain development, with cell proliferation, differentiation, migration, synaptogenesis, apoptosis, and myelination occurring in different regions during precise periods ([@r36]). Our recent study in Inuits supported this contention, because prenatal and postnatal exposures to PCBs were associated with different behavioral end points ([@r45]).

Conclusions
===========

The ability to detect associations between postnatal exposure to POPs and decrements in children's health or development is tightly bound to our capacity to adequately estimate exposure during windows of susceptibility that are specific to the outcome of interest. Where such associations exist, the use of toxicokinetic modeling may facilitate their detection and characterization in epidemiologic studies.

Supplemental Material
=====================

###### 

Click here for additional data file.
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